Brain Stimulation from Umeå receives EU funding to reach the global market with technology for stroke rehabilitation.
Brain Stimulation has been granted 50 000 euros by the EU Horizon 2020 SME Instrument phase 1 for international market development.
The goal is to develop, verify and bring the innovation towards global market launch.
More than 2000 European companies applied for a SME Instrument and only 260 companies were accepted.
Brain Stimulation from Umeå started in 2011 with the aim of exploiting brain plasticity results from research within a new concept of rehabilitation and diagnosis of cognitive impairments of attention in stroke patients (the Neglect Syndrome).
Brain Stimulation’s innovation meets the need of early detection and diagnosis as well as efficient rehabilitation of patients in clinics and that can continue in patients’ home environment. If the Neglect Syndrome is discovered and treated faster and better than today, the wellbeing of patients will increase.
Around 30% of the 16 Million new stroke patients worldwide per year suffer from the Neglect Syndrome, i.e. there are 5-6 million new patients per year. The addressable market exceeds 6 Million patients per year, as the ambition is to reach not just the stroke patients with Neglect Syndrome but also Dementia, Traumatic Brain Injuries, Parkinson and other degenerative brain diseases.
Several university clinics in the US, the Netherlands, Switzerland, England, Finland and Sweden have already tried the technology.
“The challenge now is to start sales on the first two products and validate the new product RehAtt in augmented reality (HoloLens), also useful in home environment with e-health solution,” says Helena Fordell, CEO, researcher and founder of Brain Stimulation.
The sales part and marketing within Brain Stimulation have therefore been expanded with extra staff and with the grant from the EU initiative SME instruments, the aim is to reach new customers.